| 5-HT | 5-Hydroxy-Tryptamine = Serotonin |
|---|---|
| GSCN | giant serotonin-containing neuron |
| GSN | gelsonin; giant serotonin-containing neuron |
| 5-HT | 5-hydroxytryptamine [serotonin] |
| I5HT | intraplatelet serotonin |
| CCA | Calcium channel antagonists |
|---|---|
| H(2)RA | H(2) receptor antagonists |
| LTRA | Leukotriene receptor antagonists |
| AIIRA | angiotensin II receptor antagonists |
| [(3)H]-5-HT | 3)H]-serotonin |
thromboxane
| serotonin antagonists | Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonin agonists. (12 Dec 1998) |
|---|
| receptors, serotonin | Cell-surface proteins that bind serotonin and trigger intracellular changes which influence the behaviour of cells. Several types of serotonin receptors have been recognised which differ in their pharmacology, molecular biology, and mode of action. (12 Dec 1998) |
|---|---|
| selective serotonin reuptake inhibitor | <pharmacology> This is a class of drug that are used as antidepressants. Functionally, they increase the levels of serotonin in the body. These drugs can be dangerous if they are mixed with other drugs such as other antidepressants, illicit drugs (LSD, cocaine, methamphetamine), some antihistamines (Seldane, Histmanal), some antibiotics, and calcium channel blockers. Side effects include lethargy, confusion, flushing, sweating and muscle spasms. Overdose can cause damage to red blood cells, breathing problems and kidney damage. Examples include: Prozac, Zoloft and Paxil. Acronym: SSRI (12 Jan 1998) |
| serotonin | <biochemistry, hormone> A neurotransmitter and hormone (176 kD), found in vertebrates, invertebrates and plants. It is synthesised from the amino acid tryptophan by enterochromaffin cells in the gut and bronchi. It is metabolised to 5-HIAA in the liver and then excreted in the urine. Serotonin is measured on a venipuncture specimen in cases of suspected carcinoid syndrome (where it will be elevated). The normal range is 101 to 283 ng/ml. Acronym: 5-HT (13 Nov 1997) |
| serotonin agents | Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (12 Dec 1998) |
| serotonin agonists | Agents that have an affinity for serotonin receptors and are able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. These compounds are used as antidepressants, anxiolytics, and in the treatment of migraine. (12 Dec 1998) |
| serotonin-binding protein kinase | <enzyme> An aspect of protein kinases EC 2.7.1.37 Registry number: EC 2.7.1.- Synonym: sbp kinase (26 Jun 1999) |
| serotonin uptake inhibitors | Compounds that specifically inhibit the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. These agents have been used in treatment of depression, panic disorder, obsessive-compulsive behaviour, and alcoholism, as analgesics, and to treat obesity and bulimia. Many of the adrenergic uptake inhibitors also inhibit serotonin uptake; they are not included here. (12 Dec 1998) |
| adrenergic alpha-antagonists | Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (12 Dec 1998) |
| adrenergic antagonists | Drugs that bind to but do not activate adrenergic receptors. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters epinephrine and norepinephrine. (12 Dec 1998) |
| adrenergic beta-antagonists | Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (12 Dec 1998) |
| aldosterone antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of aldosterone. (12 Dec 1998) |
| androgen antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of androgens. (12 Dec 1998) |
| gaba antagonists | Drugs that bind to but do not activate gaba receptors, thereby blocking the actions of endogenous gaba or gaba agonists. (12 Dec 1998) |
| cholinergic antagonists | Drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. (12 Dec 1998) |
| muscarinic antagonists | Drugs that bind to but do not activate muscarinic cholinergic receptors (receptors, muscarinic), thereby blocking the actions of endogenous acetycholine or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antagonists that discriminate among the various muscarinic receptor subtypes and might allow better control of peripheral and central actions are under development. (12 Dec 1998) |
Synonyms : Antagonists, 5-HT, Antagonists, 5-Hydroxytryptamine, Antagonists, Serotonin, 5 HT Antagonists, 5 Hydroxytryptamine Antagonists, Agents, Antiserotonergic, Antagonists, 5 HT, Antagonists, 5 Hydroxytryptamine, Blockaders, Serotonin
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|